Today, we announced our second quarter earnings results. Read more about our recent highlights and outlook in our business update: https://bit.ly/4g8SdNv #CRSP
About us
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
- Website
-
http://www.crisprtx.com
External link for CRISPR Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2013
- Specialties
- Gene Editing, Hematology, and Immuno-Oncology
Locations
-
Primary
Get directions
105 West First Street
Boston, MA 02127, US
-
Get directions
Baarerstrasse 14-16
Zug, CH CH-6300, CH
-
Get directions
90 Fetter Lane
London, England EC4A 1JP, GB
-
Get directions
455 Mission Bay Blvd S
San Francisco, California 94158, US
Employees at CRISPR Therapeutics
Updates
-
Our CEO Samarth Kulkarni joined the Biotech CEO Panel at the BiotechTV U.S. Science Summit alongside Nello Mainolfi, Jason Kelly, and Kendalle Burlin O'Connell to discuss cutting-edge science and the opportunities shaping the biotech industry. Thanks to Brad Loncar and BiotechTV for bringing together leaders from across biotech for engaging conversations on scientific innovation and the path ahead.
-
-
A meaningful moment for children with sickle cell disease and transfusion-dependent beta thalassemia, and their families. The FDA has approved expanded use of a one-time CRISPR/Cas9 gene-edited treatment, co-developed with Vertex, for children as young as 2 years old with either condition. It is the first gene-edited therapy approved for children this young for both sickle cell disease and transfusion-dependent beta thalassemia. These are progressive, life-shortening diseases that can begin causing organ damage in the earliest years of life. Today's approval expands eligibility to considerably more children.
-
-
May is #NationalCancerResearchMonth, highlighting the critical role of scientific research in advancing the prevention, diagnosis, and treatment of cancer. This month we acknowledge all of the individuals working tirelessly to improve cancer outcomes. Learn more from American Association for Cancer Research: https://www.aacr.org/
-
-
May is #LupusAwarenessMonth, a time to increase understanding and awareness of #lupus, a chronic autoimmune disease that can affect many parts of the body and impact daily life in complex and unpredictable ways. Learn more from Lupus Foundation of America, Inc.: https://lnkd.in/eq-MVfV
-
-
Today is #InternationalThalassemiaDay, dedicated to increasing awareness of #thalassemia, an inherited #BloodDisorder. Living with thalassemia can involve regular health monitoring and blood transfusions. We recognize people living with thalassemia, their families, and the global advocacy community. Learn more: https://lnkd.in/d9xCNcHT
-
-
Today, we announced our first quarter earnings results. Read more about our recent highlights and outlook in our business update: https://bit.ly/42KIqWv #CRSP
-
-
Congratulations to Stuart Orkin, MD, on receiving the 2026 Breakthrough Prize in Life Sciences. Stu’s foundational research identified BCL11A as the regulatory “off switch” for fetal hemoglobin, illuminating how to reactivate fetal hemoglobin production in adults. That work laid the scientific groundwork for the first approved CRISPR-based therapy, which we pioneered for people living with sickle cell disease and transfusion-dependent beta thalassemia. Congratulations also to Katherine High, MD, a member of our Board of Directors, and to Jean Bennett, Albert Maguire, and Swee Lay Thein. https://rb.gy/9al4cy #BreakthroughPrize
-
-
March 24 is Lipoprotein(a) Awareness Day. Elevated Lipoprotein(a), or Lp(a), is an inherited and often under-recognized risk factor for cardiovascular disease. This day recognizes individuals and families affected by elevated Lp(a) and the importance of awareness and education to #KnowLpa. Learn more from the Family Heart Foundation: https://lnkd.in/gKxwiuD8
-
-
Today, we announced our fourth quarter and full year earnings results. Read more about our recent highlights and outlook in our business update: bit.ly/3ZuYsCt
-